RADx Variant Task Force Program for Assessing the Impact of Variants on SARS-CoV-2 Molecular and Antigen Tests
<italic>Goal:</italic> Monitoring the genetic diversity and emerging mutations of SARS-CoV-2 is crucial for understanding the evolution of the virus and assuring the performance of diagnostic tests, vaccines, and therapies against COVID-19. SARS-CoV-2 is still adapting to humans and, as...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
IEEE
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/02ba3987acda41658b1292e501fb96ab |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:02ba3987acda41658b1292e501fb96ab |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:02ba3987acda41658b1292e501fb96ab2021-11-24T00:03:47ZRADx Variant Task Force Program for Assessing the Impact of Variants on SARS-CoV-2 Molecular and Antigen Tests2644-127610.1109/OJEMB.2021.3116490https://doaj.org/article/02ba3987acda41658b1292e501fb96ab2021-01-01T00:00:00Zhttps://ieeexplore.ieee.org/document/9552563/https://doaj.org/toc/2644-1276<italic>Goal:</italic> Monitoring the genetic diversity and emerging mutations of SARS-CoV-2 is crucial for understanding the evolution of the virus and assuring the performance of diagnostic tests, vaccines, and therapies against COVID-19. SARS-CoV-2 is still adapting to humans and, as illustrated by B.1.1.7 (Alpha) and B.1.617.2 (Delta), lineage dynamics are fluid, and strain prevalence may change radically in a matter of months. The National Institutes of Health's Rapid Acceleration of Diagnostics (RADx<sup>SM</sup>) initiative created a Variant Task Force to assess the impact of emerging SARS-CoV-2 variants on <italic>in vitro</italic> diagnostic testing. Working in tandem with clinical laboratories, the FDA, and the CDC, the Variant Task Force uses both <italic>in silico</italic> modeling and <italic>in vitro</italic> testing to determine the effect of SARS-CoV-2 mutations on diagnostic molecular and antigen tests. Here, we offer an overview of the approach and activities of the RADx Variant Task Force to ensure test performance against emerging SARS-CoV-2 lineages.Richard CreagerJohn BlackwoodThomas PribylLeda BassitAnuradha RaoMorgan GreenleafFilipp FrankWilbur LamEric OrtlundRaymond SchinaziAlexander GreningerMia CirrincioneDale GortEmily KennedyAdam SamutaMegan ShawBrian WalshEric LaiIEEEarticleCOVID-19in vitro diagnosticsmutationsSARS-CoV-2variants of concernComputer applications to medicine. Medical informaticsR858-859.7Medical technologyR855-855.5ENIEEE Open Journal of Engineering in Medicine and Biology, Vol 2, Pp 286-290 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
COVID-19 in vitro diagnostics mutations SARS-CoV-2 variants of concern Computer applications to medicine. Medical informatics R858-859.7 Medical technology R855-855.5 |
| spellingShingle |
COVID-19 in vitro diagnostics mutations SARS-CoV-2 variants of concern Computer applications to medicine. Medical informatics R858-859.7 Medical technology R855-855.5 Richard Creager John Blackwood Thomas Pribyl Leda Bassit Anuradha Rao Morgan Greenleaf Filipp Frank Wilbur Lam Eric Ortlund Raymond Schinazi Alexander Greninger Mia Cirrincione Dale Gort Emily Kennedy Adam Samuta Megan Shaw Brian Walsh Eric Lai RADx Variant Task Force Program for Assessing the Impact of Variants on SARS-CoV-2 Molecular and Antigen Tests |
| description |
<italic>Goal:</italic> Monitoring the genetic diversity and emerging mutations of SARS-CoV-2 is crucial for understanding the evolution of the virus and assuring the performance of diagnostic tests, vaccines, and therapies against COVID-19. SARS-CoV-2 is still adapting to humans and, as illustrated by B.1.1.7 (Alpha) and B.1.617.2 (Delta), lineage dynamics are fluid, and strain prevalence may change radically in a matter of months. The National Institutes of Health's Rapid Acceleration of Diagnostics (RADx<sup>SM</sup>) initiative created a Variant Task Force to assess the impact of emerging SARS-CoV-2 variants on <italic>in vitro</italic> diagnostic testing. Working in tandem with clinical laboratories, the FDA, and the CDC, the Variant Task Force uses both <italic>in silico</italic> modeling and <italic>in vitro</italic> testing to determine the effect of SARS-CoV-2 mutations on diagnostic molecular and antigen tests. Here, we offer an overview of the approach and activities of the RADx Variant Task Force to ensure test performance against emerging SARS-CoV-2 lineages. |
| format |
article |
| author |
Richard Creager John Blackwood Thomas Pribyl Leda Bassit Anuradha Rao Morgan Greenleaf Filipp Frank Wilbur Lam Eric Ortlund Raymond Schinazi Alexander Greninger Mia Cirrincione Dale Gort Emily Kennedy Adam Samuta Megan Shaw Brian Walsh Eric Lai |
| author_facet |
Richard Creager John Blackwood Thomas Pribyl Leda Bassit Anuradha Rao Morgan Greenleaf Filipp Frank Wilbur Lam Eric Ortlund Raymond Schinazi Alexander Greninger Mia Cirrincione Dale Gort Emily Kennedy Adam Samuta Megan Shaw Brian Walsh Eric Lai |
| author_sort |
Richard Creager |
| title |
RADx Variant Task Force Program for Assessing the Impact of Variants on SARS-CoV-2 Molecular and Antigen Tests |
| title_short |
RADx Variant Task Force Program for Assessing the Impact of Variants on SARS-CoV-2 Molecular and Antigen Tests |
| title_full |
RADx Variant Task Force Program for Assessing the Impact of Variants on SARS-CoV-2 Molecular and Antigen Tests |
| title_fullStr |
RADx Variant Task Force Program for Assessing the Impact of Variants on SARS-CoV-2 Molecular and Antigen Tests |
| title_full_unstemmed |
RADx Variant Task Force Program for Assessing the Impact of Variants on SARS-CoV-2 Molecular and Antigen Tests |
| title_sort |
radx variant task force program for assessing the impact of variants on sars-cov-2 molecular and antigen tests |
| publisher |
IEEE |
| publishDate |
2021 |
| url |
https://doaj.org/article/02ba3987acda41658b1292e501fb96ab |
| work_keys_str_mv |
AT richardcreager radxvarianttaskforceprogramforassessingtheimpactofvariantsonsarscov2molecularandantigentests AT johnblackwood radxvarianttaskforceprogramforassessingtheimpactofvariantsonsarscov2molecularandantigentests AT thomaspribyl radxvarianttaskforceprogramforassessingtheimpactofvariantsonsarscov2molecularandantigentests AT ledabassit radxvarianttaskforceprogramforassessingtheimpactofvariantsonsarscov2molecularandantigentests AT anuradharao radxvarianttaskforceprogramforassessingtheimpactofvariantsonsarscov2molecularandantigentests AT morgangreenleaf radxvarianttaskforceprogramforassessingtheimpactofvariantsonsarscov2molecularandantigentests AT filippfrank radxvarianttaskforceprogramforassessingtheimpactofvariantsonsarscov2molecularandantigentests AT wilburlam radxvarianttaskforceprogramforassessingtheimpactofvariantsonsarscov2molecularandantigentests AT ericortlund radxvarianttaskforceprogramforassessingtheimpactofvariantsonsarscov2molecularandantigentests AT raymondschinazi radxvarianttaskforceprogramforassessingtheimpactofvariantsonsarscov2molecularandantigentests AT alexandergreninger radxvarianttaskforceprogramforassessingtheimpactofvariantsonsarscov2molecularandantigentests AT miacirrincione radxvarianttaskforceprogramforassessingtheimpactofvariantsonsarscov2molecularandantigentests AT dalegort radxvarianttaskforceprogramforassessingtheimpactofvariantsonsarscov2molecularandantigentests AT emilykennedy radxvarianttaskforceprogramforassessingtheimpactofvariantsonsarscov2molecularandantigentests AT adamsamuta radxvarianttaskforceprogramforassessingtheimpactofvariantsonsarscov2molecularandantigentests AT meganshaw radxvarianttaskforceprogramforassessingtheimpactofvariantsonsarscov2molecularandantigentests AT brianwalsh radxvarianttaskforceprogramforassessingtheimpactofvariantsonsarscov2molecularandantigentests AT ericlai radxvarianttaskforceprogramforassessingtheimpactofvariantsonsarscov2molecularandantigentests |
| _version_ |
1718416072836644864 |